home / stock / iobt / iobt articles

IOBT Articles, IO Biotech Inc.

Stock Information
Company Name: IO Biotech Inc.
Stock Symbol: IOBT
Market: NASDAQ
Website: iobiotech.com
Menu
IOBT IOBT Quote IOBT Short IOBT News IOBT Articles IOBT Message Board
Get IOBT Alerts

News, Short Squeeze, Breakout and More Instantly...
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | Benzinga

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modul...
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer | Benzinga

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modul...

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting | Benzinga

New nonclinical data strengthen evidence of individual contribution of IO102 and IO103 in controlling tumor growth NEW YORK, March 06, 2024 (G...

IO Biotech to Present at 44th Annual Cowen Health Care Conference | Benzinga

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modula...
Top 5 Health Care Stocks That May Crash This Month | Benzinga

As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...

Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial r...

IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying | Benzinga

The Dow Jones closed higher by over 100 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around th...
IO Biotech Announces 2023 Third Quarter Results | Benzinga

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA® ...

IO Biotech Appoints Helen Collins, MD, to its Board of Directors | Benzinga

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modula...

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting | Benzinga

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune modula...
Next 10